{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:54:37Z","timestamp":1776315277354,"version":"3.50.1"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Tigilanol tiglate (TT; Stelfonta) is a novel intratumoral injection approved for the treatment of non-metastatic canine mast cell tumors (MCTs). Although the majority of reported adverse effects are localized and self-limiting, this case describes severe systemic and wound complications in a 10-year-old male Vizsla treated with a single 2\u202fmL intratumoral injection for a subcutaneous mast cell tumor on the left lateral hock. Within 24\u202fh, the dog developed vomiting, diarrhea, hypovolemic shock, and pancreatitis, requiring hospitalization and intensive supportive care. The cause of these systemic complications could not be definitively linked to Stelfonta, as multiple alternative diagnoses were also possible. Local tissue necrosis and wound infection subsequently progressed despite repeated surgical debridement, open wound management, and antibiotic therapy, culminating in distal limb necrosis and coxofemoral amputation 8\u202fweeks post-injection. Histopathology confirmed proximal cicatrix formation, necrosuppurative inflammation, and fibrosis without residual neoplasia. This case highlights that while TT can be effective for local tumor control, clinicians must recognize the potential for rare but severe localized complications that may require surgical intervention.<\/jats:p>","DOI":"10.3389\/fvets.2026.1757258","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:21:07Z","timestamp":1776313267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Severe wound formation following intratumoral tigilanol tiglate treatment resulting in limb amputation in a 10-year-old male dog"],"prefix":"10.3389","volume":"13","author":[{"given":"Liam","family":"Kitson","sequence":"first","affiliation":[{"name":"Department of Surgery, Guardian Veterinary Specialists","place":["Brewster, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey J.","family":"Runge","sequence":"additional","affiliation":[{"name":"Department of Surgery, Guardian Veterinary Specialists","place":["Brewster, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Shay","sequence":"additional","affiliation":[{"name":"Department of Surgery, Guardian Veterinary Specialists","place":["Brewster, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/cells11040618","article-title":"Diagnosis, prognosis and treatment of canine cutaneous and subcutaneous mast cell Tumors","volume":"11","author":"De Nardi","year":"2022","journal-title":"Cells"},{"key":"ref2","volume-title":"Withrow and Macewen\u2019s Small Animal Clinical Oncology","author":"Vail","year":"2020"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e006602","DOI":"10.1136\/jitc-2022-006602","article-title":"Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade. Journal for ImmunoTherapy of","volume":"12","author":"Cullen","year":"2024","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/jvim.15806","article-title":"Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46)","volume":"35","author":"De Ridder","year":"2021","journal-title":"J Vet Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3389\/fvets.2020.00639","article-title":"Use of the Intratumoural anticancer drug Tigilanol Tiglate in two horses","volume":"7","author":"De Ridder","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10637-018-0604-y","article-title":"Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate","volume":"37","author":"Barnett","year":"2019","journal-title":"Investig New Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ebiom.2019.11.037","article-title":"Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46)","volume":"50","author":"Panizza","year":"2019","journal-title":"EBioMedicine"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.3389\/fimmu.2018.01900","article-title":"Inflammasomes in tissue damages and immune disorders after trauma","volume":"9","author":"Bortolotti","year":"2018","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/J.CVSM.2023.12.010","article-title":"Updates in surgical oncology","volume":"54","author":"S\u00e9guin","year":"2024","journal-title":"Vet Clin N Am Small Anim Pract"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/jvim.16009","article-title":"Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate","volume":"35","author":"Reddell","year":"2021","journal-title":"J Vet Intern Med"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1757258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:21:08Z","timestamp":1776313268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1757258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":10,"alternative-id":["10.3389\/fvets.2026.1757258"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2026.1757258","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"1757258"}}